FIELD: biochemistry, molecular biology.
SUBSTANCE: invention proposes a peptide that represents fragment of human κ-casein and possessing apoptotic activity with respect to breast adenocarcinoma cultured cells. The claimed peptide is isolated from female milk and represents fragment of human κ-casein comprising 74 amino acid residues, molecular mass about 8.6 kDa and found amino acid sequence encoded by the nucleotide sequence SEQ ID NO:1 given in the invention description. Proposed peptide (lacaptin) induces death of cells MCF-7 in its minimal concentration 10 mcg/ml, stops proliferation of cellular culture and causes death of about 10% of cells for 12 h. Increasing concentration of peptide to 100 mcg/ml results to death of 50-70% of breast adenocarcinoma MCF-7 cells for 12 h. Peptide can be used in medicine as abase for development of medicinal formulation of peptide preparation used in therapy of malignant neoplasms.
EFFECT: valuable medicinal properties of peptide.
1 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| STRAIN OF HYBRID CULTIVATED CELLS OF ANIMALS Mus Musculus, PRODUCING MONOCLONAL ANTIBODIES, SPECIFIC TO PEPTIDE, WHICH POSSESSES APOPTOTIC ACTIVITY WITH RESPECT TO CANCER CELLS | 2009 |
|
RU2402605C1 |
| FRACTION OF DNA-HYDROLYSE SECRETORY IMMUNOGLOBULINS OF CLASS A, WITH SELECTIVE APOPTOTIC ACTIVITY IN RELATION TO HUMAN CANCER CELLS | 2015 |
|
RU2605321C1 |
| METHOD FOR EXTRACTING AND PURIFYING RECOMBINANT PROTEIN, AN ANALOGUE OF A HUMAN KAPPA-CASEIN FRAGMENT HAVING CYTOTOXIC ACTIVITY TOWARDS HUMAN CANCER CELLS | 2018 |
|
RU2693251C1 |
| RECOMBINANT PLASMID DNA pFK2 PROVIDING SYNTHESIS OF RECOMBINANT PEPTIDE BEING HUMAN KAPPA CASEIN FRAGMENT ANALOGUE, METHOD FOR PREPARING RECOMBINANT PEPTIDE, AND RECOMBINANT PEPTIDE, HUMAN KAPPA CASEIN FRAGMENT ANALOGUE EXHIBITING APOPTOTIC ACTIVITY IN RELATION TO MALIGNANT CELLS | 2009 |
|
RU2401307C1 |
| RECOMBINANT PLASMID pET-15b_T1_RL DNA PROVIDING SYNTHESIS OF RECOMBINANT FUSION PROTEIN CONSISTING OF TUMOR-SPECIFIC PEPTIDES AND ANTITUMOR PEPTIDE RL2, AND RECOMBINANT FUSION PROTEIN POSSESSING CYTOTOXIC ACTIVITY AGAINST CANCER CELLS AND TARGETED PROPERTIES AGAINST TUMOR TISSUE | 2016 |
|
RU2619050C1 |
| METHOD OF TREATING MALIGNANCIES IN MAMMALS | 2011 |
|
RU2461566C1 |
| RECOMBINANT PLASMID pET-15b_T3_RL DNA PROVIDING SYNTHESIS OF RECOMBINANT FUSION PROTEIN CONSISTING OF TUMOR-SPECIFIC PEPTIDES AND ANTITUMOR PEPTIDE RL2, AND RECOMBINANT FUSION PROTEIN POSSESSING ANTI-TUMOR ACTIVITY AGAINST HUMAN BREAST CANCER | 2016 |
|
RU2619053C1 |
| RECOMBINANT EL1 PEPTIDE HAVING CYTOTOXIC ACTIVITY RELATIVE TO HUMAN CANCER CELLS | 2017 |
|
RU2683221C1 |
| RECOMBINANT STRAIN OF VV-GMCSF-S-Lact VACCINIA VIRUS, WITH ONCOLYTIC ACTIVITY, PRODUCING GRANULOCYTOR-MACROPHAGAL COLONY-STIMULATING HUMAN FACTOR AND SECRETED FORM OF LACTAPTIN ONCOTOXIC PROTEIN | 2016 |
|
RU2621861C1 |
| RECOMBINANT OF VV-GMCSF / LACT-DGF VIRUS OF OSVOVICINE, OF ONLY-COLIC ACTIVITY AND PRODUCING SECRETABLE CHIMERIC WHITE, CONTAINING FROM GRANULOCYTE-MACROPHAGAL COLONISTIMULATING HUMAN FACTOR AND ONCOTOXIC PROTEIN OF LACTAPTIN | 2016 |
|
RU2630672C1 |
